It is difficult for the doctors to threat the patients in a situation where there is lack of essential medicines as they are too expensive and even due to non-production of some particular medicines . Sometimes, the doctors for treatment need specific medicines and have to use medicines that are highly toxic and ineffective as nobody looks for a better cure. For medical humanitarian organization, it is becoming difficult for them to have easy access to the essential medicines mainly for the medicines used for the most common global infectious diseases.
The various pharmaceutical companies have always faced criticism for not actively making efforts for promoting easy affordability and availability of essential medicines mainly in poor and developing nations. Positive results are yielded by some of the essential drug manufacturers such as Glaxo Smith Kline and Johnson and Johnson for criticism for intensifying their initiatives leaned at ensuring the affordability and availability of the essential drugs in less affluent markets. According to the “Access to Medicine Index” published in 2012, the response of the drug manufacturers towards rising social pressure for providing affordable drugs. A range of initiatives undertaken by the drug makers for a wide range of actions such as reduced and differential pricing, technological transfers under licensed agreements and donations (Patel, Gauld, Norris, and Rades, 2012, p. 297). The proportion of poor economic group is high in developing countries that prove to be a constraint in making the essential medicines affordable for individuals as they are not stable enough to afford essential medicines. The easy availability of medicines is based on various factors such as ineffective health staff and facilities, limited investments in health systems, poor supply of essential medicines and affordability.
Effective and improved researches into improved forms of the existing drugs such as sustained action or rectal formation can make an easy access to drugs for poor population. This can also be done through the development of easy treatment guidelines such as one-shot treatments. These effective researches can only be developed in presence of financial and technical resources and especially in conditions till where new efficacy criteria are applicable for the treatment under study (Schüklenk, and Ashcroft, 2002, p.186). The government must make efforts in the establishment of national and state level utilities for ensuring a transparent system with an aim of making bulk procurements while making sufficient supply of low-cost, rational and generic essential medicines up to the lowest referrals levels that can be more effectively managed by the IT enabled system. With the help of improved transportation, effective data and supply chain management, effectively organized referral systems, effective human resource management and updated facilities are essential for ensuring easy accessibility and availability of essential medicines.